Long-term outcomes and failure patterns of definitive radiotherapy for cervical esophageal carcinoma.
- Author:
Xuan LIU
1
;
Jing Wei LUO
1
;
Zong Mei ZHOU
1
;
Run Ye WU
1
;
Ye ZHANG
1
;
Kai WANG
1
;
Xue Song CHEN
1
;
Yuan QU
1
;
Xiao Dong HUANG
1
;
Xi WANG
1
;
Nan BI
1
;
Qin Fu FENG
1
;
Ji Ma LYU
1
;
Dong Fu CHEN
1
;
Ze Fen XIAO
1
;
Jian Ping XIAO
1
;
Jun Lin YI
1
;
Li GAO
1
Author Information
- Publication Type:Journal Article
- Keywords: Concurrent chemoradiotherapy; Esophageal neoplasms; Prognosis; Radiotherapy
- MeSH: Humans; Retrospective Studies; Esophageal Neoplasms/pathology*; Carcinoma/drug therapy*; Prognosis; Treatment Outcome; Chemoradiotherapy/methods*; Radiotherapy Dosage
- From: Chinese Journal of Oncology 2022;44(10):1125-1131
- CountryChina
- Language:Chinese
- Abstract: Objective: To evaluate the long-term outcomes, failure patterns and prognostic factors of definitive radiotherapy in patients with cervical esophageal carcinoma (CEC). Methods: We retrospectively reviewed the clinical data of 148 CEC patients who treated with definitive radiotherapy in Cancer Hospital of Chinese Academy of Medical Sciences from January 2001 to December 2017. The median radiation dose was 66 Gy (59.4-70 Gy) and 33.1% of patients received concurrent chemotherapy. The Kaplan-Meier method was used to calculate survival rates. The log rank test was used for survival comparison and univariate prognostic analysis. The Cox model was used for multivariate prognostic analysis. Results: The median follow-up time was 102.6 months. The median survival time, 2- and 5-year overall survival (OS) were 22.7 months, 49.9% and 28.3%. The median, 2- and 5-year progression-free survival were 12.6 months, 35.8% and 25.8%. The 2- and 5-year locoregional recurrence-free survival were 59.1% and 50.8%. The 2- and 5-year distant metastases-free survival were 74.6% and 65.9%. Multivariate analysis showed that EQD(2)>66 Gy was the only independent prognostic indicator for OS (P=0.040). The median survival time and 5-year OS rate significantly improved in patients who received EQD(2)>66 Gy than those who received≤66 Gy (31.2 months vs. 19.2 months, 40.1% vs. 19.1%, P=0.027). A total of 87 patients (58.8%) developed tumor progression. There were 50 (33.8%), 23 (15.5%) and 39 (26.4%) patients developed local, regional recurrence and distant metastases, respectively. Eleven patients (7.4%) underwent salvage surgery, and the laryngeal preservation rate for entire group was 93.9%. Conclusions: Definitive radiotherapy is an effective treatment for cervical esophageal carcinoma with the advantage of larynx preservation. Local recurrence is the major failure pattern. EQD(2)>66 Gy is associated with the improved overall survival.
